The misfolded pro-inflammatory protein S100A9 disrupts memory via neurochemical remodelling instigating an Alzheimer’s disease-like cognitive deficit

Memory deficits may develop from a variety of neuropathologies including Alzheimer's disease dementia. During neurodegenerative conditions there are contributory factors such as neuroinflammation and amyloidogenesis involved in memory impairment. In the present study, dual properties of S100A9 protein as a pro-inflammatory and amyloidogenic agent were explored in the passive avoidance memory task along with neurochemical assays in the prefrontal cortex and hippocampus of aged mice. S100A9 oligomers and fibrils were generated in vitro and verified by AFM, Thioflavin T and A11 antibody binding. Native S100A9 as well as S100A9 oligomers and fibrils or their combination were administered intranasally over 14 days followed by behavioral and neurochemical analysis. Both oligomers and fibrils evoked amnestic activity which correlated with disrupted prefrontal cortical and hippocampal dopaminergic neurochemistry. The oligomer-fibril combination produced similar but weaker neurochemistry to the fibrils administered alone but without passive avoidance amnesia. Native S100A9 did not modify memory task performance even though it generated a general and consistent decrease in monoamine levels (DA, 5-HT and NA) and increased metabolic marker ratios of DA and 5-HT turnover (DOPAC/DA, HVA/DA and 5-HIAA) in the prefrontal cortex. These results provide insight into a novel pathogenetic mechanism underlying amnesia in a fear-aggravated memory task based on amyloidogenesis of a pro-inflammatory factor leading to disrupted brain neurochemistry in the aged brain. The data further suggests that amyloid species of S100A9 create deleterious effects principally on the dopaminergic system and this novel finding might be potentially exploited during dementia management through a neuroprotective strategy.

[1]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[2]  W. Bowers,et al.  Tumor Necrosis Factor-α Potentiates Intraneuronal Ca2+ Signaling via Regulation of the Inositol 1,4,5-Trisphosphate Receptor* , 2008, Journal of Biological Chemistry.

[3]  K. Yanamandra,et al.  Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine , 2013, Behavioural Brain Research.

[4]  T. Vogl,et al.  Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. , 2003, Trends in immunology.

[5]  Keith A. Johnson,et al.  Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.

[6]  M. Hüll,et al.  Microglial activation in Alzheimer's disease. , 2009, Current Alzheimer research.

[7]  J. Ruysschaert,et al.  Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. , 2015, The Biochemical journal.

[8]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[9]  J. D. McGaugh,et al.  Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. , 2012, Learning & memory.

[10]  Y. Suh,et al.  S100a9 Knockdown Decreases the Memory Impairment and the Neuropathology in Tg2576 Mice, AD Animal Model , 2010, PloS one.

[11]  S. Salamat,et al.  Oncogenic Kras Expression in Postmitotic Neurons Leads to S100A8-S100A9 Protein Overexpression and Gliosis* , 2012, The Journal of Biological Chemistry.

[12]  W. Nacken,et al.  S100A9 Knockout Decreases the Memory Impairment and Neuropathology in Crossbreed Mice of Tg2576 and S100A9 Knockout Mice Model , 2014, PloS one.

[13]  Robert Lalonde,et al.  Relations between open-field, elevated plus-maze, and emergence tests as displayed by C57/BL6J and BALB/c mice , 2008, Journal of Neuroscience Methods.

[14]  M. Zarrindast,et al.  Influence of morphine on medial prefrontal cortex alpha2 adrenergic system in passive avoidance learning in rats , 2015, Pharmacology Biochemistry and Behavior.

[15]  C. Belzung,et al.  The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. , 2003, European journal of pharmacology.

[16]  K. Wada,et al.  Stress-induced impairment of inhibitory avoidance learning in female neuromedin B receptor-deficient mice , 2003, Physiology & Behavior.

[17]  S. Shankar,et al.  The role of pro-inflammatory S100A9 in Alzheimer’s disease amyloid-neuroinflammatory cascade , 2013, Acta Neuropathologica.

[18]  Elizabeth Head,et al.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.

[19]  R. Sewell,et al.  Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms , 2015, Behavioural Brain Research.

[20]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[21]  R. Donato,et al.  Functions of S100 proteins. , 2012, Current molecular medicine.

[22]  P. Hof,et al.  Does Alzheimer's disease begin in the brainstem? , 2009, Neuropathology and applied neurobiology.

[23]  K. Rayevsky,et al.  Modeling of presymptomatic and symptomatic stages of parkinsonism in mice , 2011, Neuroscience.

[24]  B. Austen,et al.  Amyloid-β Acts as a Regulator of Neurotransmitter Release Disrupting the Interaction between Synaptophysin and VAMP2 , 2012, PloS one.

[25]  R. Veerhuis,et al.  Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology , 2006, International Journal of Developmental Neuroscience.

[26]  R. Sewell,et al.  Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmitters , 2007, Journal of Neuroimmunology.

[27]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[28]  J. Segura-Aguilar,et al.  Protective and toxic roles of dopamine in Parkinson's disease , 2014, Journal of neurochemistry.

[29]  C. Dobson,et al.  Antibodies and protein misfolding: From structural research tools to therapeutic strategies. , 2014, Biochimica et biophysica acta.

[30]  D. Zimmer,et al.  The Ca2+ sensor S100A1 modulates neuroinflammation, histopathology and Akt activity in the PSAPP Alzheimer's disease mouse model. , 2014, Cell calcium.

[31]  S. Phipps,et al.  RAGE and TLRs: relatives, friends or neighbours? , 2013, Molecular immunology.

[32]  Norbert Sachser,et al.  Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer’s disease , 2009, Neurobiology of Aging.

[33]  E. Mufson,et al.  Nigrostriatal Dysfunction in Familial Alzheimer's Disease-Linked APPswe/PS1ΔE9 Transgenic Mice , 2005, The Journal of Neuroscience.

[34]  L. Lue,et al.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.

[35]  Hugo M. Botelho,et al.  Natural and amyloid self‐assembly of S100 proteins: structural basis of functional diversity , 2010, The FEBS journal.

[36]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[37]  O. Mutlu,et al.  Effects of 7-NI and ODQ on memory in the passive avoidance, novel object recognition, and social transmission of food preference tests in mice , 2014, Medical science monitor basic research.

[38]  George Perry,et al.  Transgenic Mouse Models of Alzheimer’s Disease: Behavioral Testing and Considerations , 2009 .

[39]  N. Pivac,et al.  Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review. , 2015, Psychiatria Danubina.

[40]  L. Nyberg,et al.  Linking cognitive aging to alterations in dopamine neurotransmitter functioning: Recent data and future avenues , 2010, Neuroscience & Biobehavioral Reviews.

[41]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[42]  J. Seamans,et al.  Selective Roles for Hippocampal, Prefrontal Cortical, and Ventral Striatal Circuits in Radial-Arm Maze Tasks With or Without a Delay , 1997, The Journal of Neuroscience.

[43]  Martin Sarter,et al.  Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss , 2015, Behavioural Brain Research.

[44]  Joseph P Huston,et al.  Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.

[45]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[46]  L. Lue,et al.  Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.

[47]  L. Chew,et al.  S100A9 induces aggregation-prone conformation in Abeta peptides: a combined experimental and simulation study , 2013 .

[48]  G. Miller,et al.  Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2002, Experimental Neurology.

[49]  J. Gilthorpe,et al.  MRP14 (S100A9) Protein Interacts with Alzheimer Beta-Amyloid Peptide and Induces Its Fibrillization , 2012, PloS one.

[50]  O. Forlenza,et al.  Alzheimer's disease. , 2012, Sub-cellular biochemistry.

[51]  G. Arendash,et al.  Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease , 2009, Glia.

[52]  E. Masliah,et al.  Molecular mechanisms of neurodegeneration in Alzheimer's disease. , 2010, Human molecular genetics.

[53]  Y. Suh,et al.  The Role of S100a9 in the Pathogenesis of Alzheimer’s Disease: The Therapeutic Effects of S100a9 Knockdown or Knockout , 2012, Neurodegenerative Diseases.

[54]  Teruhiko Yoshida,et al.  Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE , 2015, The Journal of Immunology.

[55]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[56]  S. Tonegawa,et al.  Differentiation of forebrain and hippocampal dopamine 1‐class receptors, D1R and D5R, in spatial learning and memory , 2015, Hippocampus.

[57]  M. Tiwari,et al.  β-Amyloid pathogenesis: Chemical properties versus cellular levels , 2016, Alzheimer's & Dementia.

[58]  L. Colgin Oscillations and hippocampal–prefrontal synchrony , 2011, Current Opinion in Neurobiology.

[59]  C. Barrow,et al.  Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. , 2002, Current medicinal chemistry.

[60]  C. Dobson,et al.  The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.

[61]  C. Cotman,et al.  In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.

[62]  Bill Y. Lin,et al.  Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care , 2013, Neuroscience & Biobehavioral Reviews.

[63]  T. Vogl,et al.  Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. , 2006, Biochimica et biophysica acta.

[64]  G. Barker,et al.  When Is the Hippocampus Involved in Recognition Memory? , 2011, The Journal of Neuroscience.

[65]  P. Rouleau,et al.  Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.

[66]  G. Cole,et al.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.

[67]  M. Benson,et al.  Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[68]  Sofia B. Carvalho,et al.  Intrinsically Disordered and Aggregation Prone Regions Underlie β-Aggregation in S100 Proteins , 2013, PloS one.

[69]  Marco Bozzali,et al.  Dopaminergic Modulation of Cortical Plasticity in Alzheimer’s Disease Patients , 2014, Neuropsychopharmacology.

[70]  R. Sewell,et al.  Autoimmune Responses to Amyloid Structures of Aβ(25–35) Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.

[71]  G. Halliday,et al.  Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease , 2006, Neurobiology of Aging.

[72]  T. Vogl,et al.  Pro-Inflammatory S100A8 and S100A9 Proteins: Self-Assembly into Multifunctional Native and Amyloid Complexes , 2012, International journal of molecular sciences.

[73]  J. Becker,et al.  Extrapyramidal signs in patients with probable Alzheimer disease. , 1997, Archives of neurology.

[74]  F. Kametani S100A9/Mrp14 Plays an Important Role in Ab Amyloidosis Enhancement , 2014 .

[75]  G. Koch,et al.  “Is dopamine involved in Alzheimer's disease?” , 2014, Front. Aging Neurosci..

[76]  M. Agaibyi S100 Protein Family and its Application in Clinical Practice , 2016 .

[77]  P. Mcgeer,et al.  Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. , 2010, Journal of Alzheimer's disease : JAD.

[78]  C. Dobson,et al.  Bridging the gap: From protein misfolding to protein misfolding diseases , 2009, FEBS letters.

[79]  Vivian V. Valentin,et al.  Differential effects of dopamine-directed treatments on cognition , 2015, Neuropsychiatric disease and treatment.